Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:GRCL

Gracell Biotechnologies - GRCL Stock Forecast, Price & News

$3.37
-0.11 (-3.16%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$3.37
$3.37
50-Day Range
$2.08
$3.96
52-Week Range
$1.68
$7.96
Volume
1,600 shs
Average Volume
154,599 shs
Market Capitalization
$228.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Gracell Biotechnologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
345.1% Upside
$15.00 Price Target
Short Interest
Bearish
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Gracell Biotechnologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.29) to ($0.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

693rd out of 1,044 stocks

Pharmaceutical Preparations Industry

326th out of 510 stocks

GRCL stock logo

About Gracell Biotechnologies (NASDAQ:GRCL) Stock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

GRCL Stock News Headlines

Gracell Biotechnologies Inc. Misses Q2 EPS by 15c
See More Headlines
Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

GRCL Company Calendar

Last Earnings
11/14/2022
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/13/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRCL
Fax
N/A
Employees
348
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+345.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-70,890,000.00
Pretax Margin
-154,287.73%

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$3.17 per share

Miscellaneous

Free Float
48,725,000
Market Cap
$228.06 million
Optionable
Not Optionable
Beta
-2.46

Key Executives

  • Dr. Wei Cao (Age 63)
    Founder, Chairman & CEO
  • Dr. Yili Xie M.B.A. (Age 51)
    Ph.D., Chief Financial Officer
  • Dr. Yajin Ni M.D. (Age 59)
    Ph.D., Chief Technology Officer
  • Dr. Samuel Suhua Zhang M.B.A.
    Ph.D., Chief Bus. Officer
  • Dr. Wendy Li M.D.
    Chief Medical Officer
  • Ms. Erin Li
    Exec. Officer













GRCL Stock - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRCL shares.
View GRCL analyst ratings
or view top-rated stocks.

What is Gracell Biotechnologies' stock price forecast for 2023?

4 Wall Street research analysts have issued 1-year price targets for Gracell Biotechnologies' stock. Their GRCL share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 345.1% from the stock's current price.
View analysts price targets for GRCL
or view top-rated stocks among Wall Street analysts.

How have GRCL shares performed in 2022?

Gracell Biotechnologies' stock was trading at $6.04 at the beginning of the year. Since then, GRCL stock has decreased by 44.2% and is now trading at $3.37.
View the best growth stocks for 2022 here
.

When is Gracell Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our GRCL earnings forecast
.

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.27.

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO.

What is Gracell Biotechnologies' stock symbol?

Gracell Biotechnologies trades on the NASDAQ under the ticker symbol "GRCL."

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.41%), Balyasny Asset Management LLC (0.04%) and Tower Research Capital LLC TRC (0.01%).

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gracell Biotechnologies' stock price today?

One share of GRCL stock can currently be purchased for approximately $3.37.

How much money does Gracell Biotechnologies make?

Gracell Biotechnologies (NASDAQ:GRCL) has a market capitalization of $228.05 million and generates $60,000.00 in revenue each year. The company earns $-70,890,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Gracell Biotechnologies have?

The company employs 348 workers across the globe.

How can I contact Gracell Biotechnologies?

The official website for the company is www.gracellbio.com. The company can be reached via phone at 86-512-6262-6701 or via email at ir@gracellbio.com.

This page (NASDAQ:GRCL) was last updated on 11/28/2022 by MarketBeat.com Staff